Description
Kimmtrak (tebentafusp-tebn) is a prescription cancer medicine used to treat adult patients with unresectable or metastatic uveal melanoma, a rare type of eye cancer. It is a bispecific T-cell engager (ImmTAC) that targets the gp100 protein on melanoma cells and CD3 receptors on T cells. By binding to both, Kimmtrak redirects the patient’s own immune system to recognize and destroy cancer cells.
Reviews
There are no reviews yet.